Interview with Hervé Dussart , President, AstraZeneca Turkey
Even though you have delivered strong results in most of the markets you have been appointed, this is your first assignment as the head of a subsidiary. For a man…
Since 1999 with the mission to produce ideas that add value for the life of people spend their lives working for better quality, and performs a lot of research, AstraZeneca, has been undertaking major projects in Turkey within the framework of social responsibility.
AstraZeneca develops prescription drugs, and carry’s out all production and marketing and presentation of these services in the field, as one of the most important international companies in the industry. With global sales on track to reach USD 50 billion by 2025, AstraZeneca provides medications for the areas of cardiology, gastroenterology, oncology, central nervous system, respiratory disease, and diabetes.
Contact
Istanbul
AstraZeneca İlaç San. ve Tic. Ltd. Şti.
Büyükdere Cad. Yapı Kredi Plaza B Blok K:3-4 Levent Istanbul
Istanbul
34330
+90 212 317 23 00
+90 212 317 23 15
http://www.astrazeneca.com/Turkey
Even though you have delivered strong results in most of the markets you have been appointed, this is your first assignment as the head of a subsidiary. For a man…
PharmaBoardroom talked to Sr. Managing Director of Medtronic Turkey, Ayhan Ozturk about improving patient outcomes, how the company introduced a whole new standard on integrated healthcare, and their recent USD $25 million…
Umut Gökalp, managing director of Japan’s Sysmex in Turkey – a company specialising in in-vitro diagnostics – evaluates their approach to developing business opportunities in the Turkish medical device sector. He also…
Sevi Firat, Founding Partner of Firat Izgi discusses the legal challenges facing pharmaceutical companies looking to penetrate the healthcare market in Turkey, the evolution of the legal landscape and her…
Tuğçe Koç describes the company’s initial aspirations in targeting the higher value-added therapeutic area of oncology and the type of market opportunities that are present domestically and internationally. With over…
A founding partner of YükselKarkınKüçük, Gökhan Gökçe discusses the firm’s involvement with several high profile cases concerning the healthcare and life science sector’s reference pricing system, and also elaborates on…
The managing director of DHL Express Turkey, Markus Reckling highlights the strategic importance of Turkey to the global DHL Express portfolio and elaborates on the market opportunities present for DHL’s…
The co-founder of Ekin Kimya discusses the need for greater regulation and monitoring of raw materials used in Turkish pharmaceutical manufacturing, his company’s key role as an educator and advisor…
Novartis country president Peter Catalino discusses the need for Turkey to introduce financial investment incentives to compete more effectively with other countries for investments in R&D and manufacturing. You arrived…
The chairman and CEO of Santa Farma discusses how the Turkish pharmaceutical landscape has evolved in response to the government’s healthcare transformation programs. He also enumerates various strategic initiatives the…
Omega CRO has evolved from its beginnings as a CRO contracted by local and multinational pharmaceutical companies into an organization leading clinical, epidemiological and observational studies of public interest across…
The president of the Turkish Drug and Medical Device Agency (TITCK) discusses new initiatives and reforms being carried out by his agency, including its work towards becoming a PIC/s member, and…
The CEO of Centurion shares his ambitious vision for the company’s expansion into plasma products, biotech, orphan drugs, and generic injectables over the coming years, while simultaneously developing sales in more than…
See our Cookie Privacy Policy Here
